Venous thromboembolism in cancer patients poses significant clinical challenges due to increasing incidence, multiple risk factors, and higher rates of recurrence and mortality.
Managing VTE in cancer patients involves unique challenges due to multiple risk factors and higher risks of recurrence and mortality, as highlighted by updated ASCO guidelines.
The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain about the close relationship between VTE and malignant disease. The risk of VTE among patients with cancer continues to increase and is clearly linked to patient-, disease- and treatment-specific factors. In general, VTE among patients with cancer is treated in a similar fashion to that in other patient populations. However, the greater risk of VTE in patients with cancer, the multitude of risk factors, and the greater risk of VTE recurrence and mortality among patients with cancer pose important challenges for surgeons, oncologists, and other providers.
Lyman et al. (2013) conducted a review in Venous thromboembolism in cancer. Treatment and prevention of venous thromboembolism was evaluated. Venous thromboembolism in cancer patients poses significant clinical challenges due to increasing incidence, multiple risk factors, and higher rates of recurrence and mortality.